C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma - PubMed (original) (raw)
C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma
S Mahner et al. Br J Cancer. 2008.
Abstract
Members of the Fos protein family dimerise with Jun proteins to form the AP-1 transcription factor complex. They have a central function in proliferation and differentiation of normal tissue as well as in oncogenic transformation and tumour progression. We analysed the expression of c-Fos, FosB, Fra-1 and Fra-2 to investigate the function of Fos transcription factors in ovarian cancer. A total of 101 patients were included in the study. Expression of Fos proteins was determined by western blot analysis, quantified by densitometry and verified by immunohistochemistry. Reduced c-Fos expression was independently associated with unfavourable progression-free survival (20.6, 31.6 and 51.2 months for patients with low, moderate and high c-Fos expression; P=0.003) as well as overall survival (23.8, 46.0 and 55.5 months for low, moderate and high c-Fos levels; P=0.003). No correlations were observed for FosB, Fra-1 and Fra-2. We conclude that loss of c-Fos expression is associated with tumour progression in ovarian carcinoma and that c-Fos may be a prognostic factor. These results are in contrast to the classic concept of c-Fos as an oncogene, but are supported by the recently discovered tumour-suppressing and proapoptotic function of c-Fos in various cancer types.
Figures
Figure 1
Representative results of c-Fos, FosB, Fra-1 and Fra-2 expression in ovarian carcinomas. As control, protein extracts from the ovarian cancer cell lines Ovcar5 and Ovcar8 as well as the mammary carcinoma cell line MCF7 were included in each gel. Tumour samples were coded as Txxxx and equal amounts of protein (20 _μ_g) were loaded on the gel.
Figure 2
C-Fos immunohistochemistry. (A) Moderately differentiated serous carcinoma with nuclear immunoreactivity in tumour cells (T) and weak immunostaining in nuclei of some stromal fibroblasts (S). 400 × . (B) Poorly differentiated serous carcinoma with only weak c-Fos immunostaining in tumour cells (T) and some fibroblasts (S). 400 × .
Figure 3
C-Fos expression is correlated with progression-free and overall survival (_P_=0.003). Kaplan–Meier curves were generated from 99 patients whose outcome was followed over a median period of 20 months. Patients were stratified based on low, moderate and high c-Fos expression. X axis: survival probability; Y axis: survival (months). Censored cases are indicated by vertical bars.
Similar articles
- The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas.
Milde-Langosch K, Röder H, Andritzky B, Aslan B, Hemminger G, Brinkmann A, Bamberger CM, Löning T, Bamberger AM. Milde-Langosch K, et al. Breast Cancer Res Treat. 2004 Jul;86(2):139-52. doi: 10.1023/B:BREA.0000032982.49024.71. Breast Cancer Res Treat. 2004. PMID: 15319566 - Overexpression of Fos-related antigen-1 in head and neck squamous cell carcinoma.
Mangone FR, Brentani MM, Nonogaki S, Begnami MD, Campos AH, Walder F, Carvalho MB, Soares FA, Torloni H, Kowalski LP, Federico MH. Mangone FR, et al. Int J Exp Pathol. 2005 Aug;86(4):205-12. doi: 10.1111/j.0959-9673.2005.00423.x. Int J Exp Pathol. 2005. PMID: 16045542 Free PMC article. - Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH, Heo JH, Kim TH, Kang H, Kim G, Kim J, Cho SH, An HJ. Lee YH, et al. Int J Gynecol Pathol. 2011 May;30(3):205-17. doi: 10.1097/PGP.0b013e3182063e71. Int J Gynecol Pathol. 2011. PMID: 21464733 - Fos family members: regulation, structure and role in oncogenic transformation.
Tulchinsky E. Tulchinsky E. Histol Histopathol. 2000 Jul;15(3):921-8. doi: 10.14670/HH-15.921. Histol Histopathol. 2000. PMID: 10963134 Review. - The transcription factor Fos: a Janus-type regulator in health and disease.
Durchdewald M, Angel P, Hess J. Durchdewald M, et al. Histol Histopathol. 2009 Nov;24(11):1451-61. doi: 10.14670/HH-24.1451. Histol Histopathol. 2009. PMID: 19760594 Review.
Cited by
- Drug-resilient Cancer Cell Phenotype Is Acquired via Polyploidization Associated with Early Stress Response Coupled to HIF2α Transcriptional Regulation.
Carroll C, Manaprasertsak A, Boffelli Castro A, van den Bos H, Spierings DCJ, Wardenaar R, Bukkuri A, Engström N, Baratchart E, Yang M, Biloglav A, Cornwallis CK, Johansson B, Hagerling C, Arsenian-Henriksson M, Paulsson K, Amend SR, Mohlin S, Foijer F, McIntyre A, Pienta KJ, Hammarlund EU. Carroll C, et al. Cancer Res Commun. 2024 Mar 7;4(3):691-705. doi: 10.1158/2767-9764.CRC-23-0396. Cancer Res Commun. 2024. PMID: 38385626 Free PMC article. - Role of Fra-2 in cancer.
Rampioni Vinciguerra GL, Capece M, Scafetta G, Rentsch S, Vecchione A, Lovat F, Croce CM. Rampioni Vinciguerra GL, et al. Cell Death Differ. 2024 Feb;31(2):136-149. doi: 10.1038/s41418-023-01248-4. Epub 2023 Dec 16. Cell Death Differ. 2024. PMID: 38104183 Free PMC article. Review. - Protection of c-Fos from autophagic degradation by PRMT1-mediated methylation fosters gastric tumorigenesis.
Kim E, Rahmawati L, Aziz N, Kim HG, Kim JH, Kim KH, Yoo BC, Parameswaran N, Kang JS, Hur H, Manavalan B, Lee J, Cho JY. Kim E, et al. Int J Biol Sci. 2023 Jul 15;19(12):3640-3660. doi: 10.7150/ijbs.85126. eCollection 2023. Int J Biol Sci. 2023. PMID: 37564212 Free PMC article. - Spatial resolution of cellular senescence dynamics in human colorectal liver metastasis.
Garbarino O, Lambroia L, Basso G, Marrella V, Franceschini B, Soldani C, Pasqualini F, Giuliano D, Costa G, Peano C, Barbarossa D, Annarita D, Salvati A, Terracciano L, Torzilli G, Donadon M, Faggioli F. Garbarino O, et al. Aging Cell. 2023 Jul;22(7):e13853. doi: 10.1111/acel.13853. Epub 2023 May 8. Aging Cell. 2023. PMID: 37157887 Free PMC article. - Tumor cell integrin β4 and tumor stroma E-/P-selectin cooperatively regulate tumor growth in vivo.
Genduso S, Freytag V, Schetler D, Kirchner L, Schiecke A, Maar H, Wicklein D, Gebauer F, Bröker K, Stürken C, Milde-Langosch K, Oliveira-Ferrer L, Ricklefs FL, Ewald F, Wolters-Eisfeld G, Riecken K, Unrau L, Krause L, Bohnenberger H, Offermann A, Perner S, Sebens S, Lamszus K, Diehl L, Linder S, Jücker M, Schumacher U, Lange T. Genduso S, et al. J Hematol Oncol. 2023 Mar 17;16(1):23. doi: 10.1186/s13045-023-01413-9. J Hematol Oncol. 2023. PMID: 36932441 Free PMC article.
References
- American-Cancer-Society (2007) Cancer Facts and Figures. Atlanta: American Cancer Society
- Appierto V, Villani MG, Cavadini E, Lotan R, Vinson C, Formelli F (2004) Involvement of c-Fos in fenretinide-induced apoptosis in human ovarian carcinoma cells. Cell Death Differ 11: 270–279 - PubMed
- Bakin AV, Curran T (1999) Role of DNA 5-methylcytosine transferase in cell transformation by fos. Science 283: 387–390 - PubMed
- Bamberger AM, Methner C, Lisboa BW, Stadtler C, Schulte HM, Loning T, Milde-Langosch K (1999) Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype. Int J Cancer 84: 533–538 - PubMed
- Bamberger AM, Milde-Langosch K, Rossing E, Goemann C, Loning T (2001) Expression pattern of the AP-1 family in endometrial cancer: correlations with cell cycle regulators. J Cancer Res Clin Oncol 127: 545–550 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous